Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)

作者： J. Carlson , N. Oestreicher , D. P. Lubeck , S. D. Ramsey , D. L. Veenstra

DOI: 10.1200/JCO.2007.25.18_SUPPL.7664

关键词:

摘要: 7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of 1st line treatment, but their relative economic and clinical v...

ascopubs.org 本地加速

ascopubs.org LINK 下载加速

sci-hub.st HTML 下载加速

参考文章(0)

Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)

来源期刊

我的账户

Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)

来源期刊

相似文章 4

Targeted anti-cancer therapy in the elderly.

Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827

我的账户